Meeting
2017 Genitourinary Cancers Symposium
Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial.
Authors
David Frazier Jarrard
University of Wisconsin Hosp and Clinics, Madison, WI
David Frazier Jarrard , Yu-Hui Chen , Glenn Liu , Michael Anthony Carducci , Mario A. Eisenberger , Yu-Ning Wong , Noah M. Hahn , Manish Kohli , Matthew M. Cooney , Robert Dreicer , Nicholas J. Vogelzang , Joel Picus , Daniel H. Shevrin , Maha Hussain , Jorge A. Garcia , Robert S. DiPaola , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00309985
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 181)
DOI
10.1200/JCO.2017.35.6_suppl.181
Abstract #
181
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.
First Author: Shusuke Akamatsu
Poster
2023 ASCO Annual Meeting
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Genitourinary Cancers Symposium
Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.
First Author: Tony Felefly
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
First Author: Adam B Weiner